Impact of pharmacist’s intervention on reducing cardiovascular risk in obese patients

Huete, L. García; Hernández-Martín, Marina; Aránguez, Isabel; Fernández-Alfonso, Marı́a S.

doi:10.1007/s11096-019-00856-w

Cited by 7 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this research the level of LDL showed a significant decline after CPBI under the effect of changing eating habits. Just like our results, Lee et al 18 and Huete et al 19 demonstrated that LDL cholesterol level was statistically decreased by the effect of CPBI educational program targeted food intake. Nonetheless, a systematic review studied the effect of pharmacy-based intervention on the control of dyslipidemia, revealed that, the intervention decreased the level of LDL among the intervention group but this reduction was not statistically significant.…”

Section: Discussionsupporting

confidence: 89%

“…25 On the contrary, other interventions were not associated with changes in blood pressure which attributed to different characteristics of patients and most of them almost well-controlled hypertension. 19,26 The CBPI group had a significant reduction in the WC and BMI (P = .001). Published results regarding the effectiveness of pharmaceutical care for reducing BMI and WC demonstrate considerable discrepancies.…”

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A Community Pharmacy-Based Intervention in the Matrix of Type 2 Diabetes Mellitus Outcomes (CPBI-T2DM): A Cluster Randomized Controlled Trial

Mohamed

Allam

Hamdy

et al. 2021

Clin Med Insights Endocrinol Diabetes

View full text Add to dashboard Cite

Introduction: Egypt has the ninth highest diabetes mellitus (DM) prevalence in the world. There is a growing interest in community involvement in DM management. Aim of the study: The aim of the study was to evaluate the tailored diabetes care model (DCM) implementation in Alexandria governorate by community pharmacy-based intervention (CPBI) from a clinical, humanistic, and economic aspect. Methods: This is a 6-month period cross-over cluster randomized control trial conducted in Alexandria. Ten clusters owing 10 community pharmacies (CPs) recruited 100 health insurance-deprived T2DM patients with >7% HbA1c in 6-months. The study was divided into 2 phases (3 months for each period) with a 1-month washout period in between. After CPs training on DCM, the interventional group received pictorial training for 45 minutes in first visit, and 15 minutes in weekly visits, whereas the control group patients received the usual care (UC). At baseline and end of each phase (3 months), patients had clinical and physical activity assessments, filled all forms of study questionnaire (knowledge, self-management, satisfaction, and adherence) and did all laboratory investigations (Fasting Blood Glucose [FBG]), HbA1c, protein-creatinine clearance (PCR), creatine clearance (GFR), and lipid profile. Results: There was no significant difference in the basal systolic and diastolic blood pressure between patients in the CBPI and UC groups, but the CBPI had significantly decreased the mean SBP and DBP by ( P = .008, .040, respectively). Also, significant waist circumference and BMI reductions (−5.82 cm and −1.86 kg/m2, P = .001) were observed in the CBPI. The CBPI patients achieved a greater reduction in FBG and HbA1C than the UC patients (102 mg/dL and 1.9%, respectively P < .001). Also, significant reductions in total cholesterol, LDL, and triglyceride (−6.4, −15.4, and −6.3 mg/dL respectively, P = .001) were achieved in the CBPI group. No significant differences were found in HDL, GFR, and PCR. Moreover, significant improvements of behavior, score of knowledge, self-management, satisfaction, and adherence were observed in CBPI patients. After multivariate analysis, HbA1C readings were significantly influenced by baseline HbA1C and eating habits. The cost saving for CPBI was −1581 LE per 1% HbA1c reduction. Conclusion: This is the first study in Egypt that illustrated the positive impact of pictorial DCM delivered by CPBI collaborative care on clinical, humanistic, laboratory, and economic outcomes to local T2DM patients.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

A Community Pharmacy-Based Intervention in the Matrix of Type 2 Diabetes Mellitus Outcomes (CPBI-T2DM): A Cluster Randomized Controlled Trial

Mohamed

Allam

Hamdy

et al. 2021

Clin Med Insights Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…Seventeen articles were obtained and summarized (Table 1). [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] In the past 10 years, most of the literature on pharmacy-led obesity management comes from community pharmacy initiatives worldwide (U.S., U.K., Spain, Australia, and Thailand) to implement weight-loss or weight-management programs as a service to the community. Most of the interventions used were pre/post studies to determine the effect of the pharmacist-led service.…”

Section: Clinical Pharmacists' Intervention In the Literaturementioning

confidence: 99%

“…33,34 Additionally, clinical pharmacists can discuss the implications of being overweight and the relationship of obesity with all eligible patients at every encounter to make a meaningful impact toward success. 35 T A B L E Summary of pharmacist-engaged obesity initiatives [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]…”

Section: Patient Interviewmentioning

confidence: 99%

Clinical review and role of clinical pharmacists in obesity management: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy

Clements

Albanese

D’Souza

et al. 2021

J Am Coll Clin Pharm

View full text Add to dashboard Cite

The objective of this practice and research network opinion paper was to identify literature for pharmacist-led services with obesity management, summarize clinical evidence for this disease state, and describe the role of a clinical pharmacist among patients who are overweight or have obesity. Clinical pharmacists play a critical role in the safe and effective management of obesity in both the inpatient and outpatient settings. In an outpatient setting, the role of the clinical pharmacist includes a comprehensive patient interview to design an individualized therapeutic plan involving nonpharmacological interventions with or without pharmacological interventions or surgical options. A clinical pharmacist conducts a risk-benefit analysis for pharmacological interventions. Furthermore, the potential of medications to contribute to weight gain or prevent weight loss can be reviewed by a clinical pharmacist when managing comorbid conditions. In an inpatient setting, a clinical pharmacist conducts medication reconciliation, determines appropriate supplements for nutritional deficiencies, and provides medication management for people with obesity who may or may not be undergoing bariatric surgery. In addition, a clinical pharmacist can provide thorough patient education with monitoring for transitions from hospital to the outpatient setting and subsequent follow-up visits.

show abstract

Evidence of the Impact of Interventions to Prevent Obesity

Caneiras

2022

Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy

View full text Add to dashboard Cite

Impact of pharmacist’s intervention on reducing cardiovascular risk in obese patients

Cited by 7 publications

References 19 publications

A Community Pharmacy-Based Intervention in the Matrix of Type 2 Diabetes Mellitus Outcomes (CPBI-T2DM): A Cluster Randomized Controlled Trial

A Community Pharmacy-Based Intervention in the Matrix of Type 2 Diabetes Mellitus Outcomes (CPBI-T2DM): A Cluster Randomized Controlled Trial

Clinical review and role of clinical pharmacists in obesity management: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy

Evidence of the Impact of Interventions to Prevent Obesity

Contact Info

Product

Resources

About